Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.

Zhejiang Saimo Pharmaceutical, a wholly-owned subsidiary of Hangzhou Bai Cheng Pharmaceutical Technology, has had its sitagliptin metformin extended-release tablets selected in the 12th round of national centralized drug procurement. The drug is indicated for adult patients with type 2 diabetes who are already on combination therapy with sitagliptin and metformin extended-release tablets. The selected specifications are sitagliptin phosphate 50 mg with metformin hydrochloride 500 mg, and sitagliptin phosphate 100 mg with metformin hydrochloride 1000 mg. In 2025, Saimo Pharmaceutical has not yet recorded sales revenue for this product. The company stated that if a procurement contract is subsequently signed and implemented, it will help boost product sales volume and market expansion, positively impacting future operating performance, while also noting that the signing of the procurement agreement and subsequent matters still carry uncertainty regarding their effect on performance.

Yuanjie Technology announced plans to invest approximately 4.268 billion yuan in the construction of the Yuanjie Semiconductor Technology Industrial Park project. This is one of the major announcements this evening. In addition, New Beiyang won the bid for the mail processing center equipment procurement project. Keqian Bio plans to sign a cooperative research and development agreement with Huazhong Agricultural University. Baicheng Pharma's sitagliptin metformin extended-release tablets were selected in the national centralized drug procurement. Shuangliang Energy won the bid for a 339 million yuan air-cooling EPC project. Runbang Heavy Industry's subsidiary signed a sales contract for six live fish transport vessels with a total value of approximately 2.8 billion to 3.3 billion yuan. Holike's wholly-owned subsidiary plans to invest 50 million yuan to subscribe for fund shares. HNA Holding's controlling subsidiary plans to sell 80 percent equity in HNA Resources and Environment. Dongyangguang's controlling subsidiary plans to increase capital and expand shares to introduce investors. Yaben Chemical plans to raise no more than 841 million yuan through a private placement for a pilot project producing 35 tons of high-end pharmaceutical intermediates annually. Qiangrui Technology plans to raise no more than 1.05 billion yuan through a private placement for a high-end semiconductor equipment precision components production and manufacturing project.

Hangzhou Bio-Sincerity Pharma Sci-Tech Co., Ltd. announced that its self-developed Class 1 innovative drug, BIOS0635-048 tablets, has received clinical trial approval from the National Medical Products Administration, allowing the drug to be tested as a monotherapy in advanced solid tumors. The drug acts on an epigenetic target, inhibiting endocrine receptors at the transcriptional level to overcome drug resistance, and regulating the cell cycle and MYC levels. Currently, no drug targeting this specific target has been approved for marketing globally. The company stated that this approval will not have a significant impact on its near-term performance, and there are many uncertainties in the subsequent clinical trials.